SMS Lifesciences , formerly known as SMS Lifesciences India Limited and now operating as Haleos Labs Limited, has announced a significant milestone in its international expansion efforts. The company's API manufacturing facility in Telangana has successfully completed an inspection by the Brazilian Health Authority (ANVISA), marking a crucial step towards entering the Brazilian pharmaceutical market.

Successful ANVISA Inspection

The inspection, conducted from September 22-26, 2025, focused on Haleos Labs' API manufacturing facility located at Sy. No. 180/2, Kazipally (V) Jinnaram MandaI, Sanga Reddy District, Telangana - 502319 (Unit -1). The successful completion of this audit reaffirms the company's compliance with international quality standards and opens up new opportunities for growth in South America.

Strategic Importance

Brazil represents the largest pharmaceutical market in South America, making this regulatory approval particularly significant for Haleos Labs. The company views this development as a gateway to expand its presence in the region and potentially increase its market share in the API manufacturing sector.

Company Transition

It's worth noting that Haleos Labs Limited is currently in the process of transitioning from its former name, SMS Lifesciences India Limited. The company is adopting the new name in compliance with applicable regulatory requirements. This rebranding effort coincides with the company's push for international expansion and regulatory approvals.

Management Commentary

Trupti Ranjan Mohanty, a company representative, stated, "This successful inspection reaffirms our company's compliance with international quality standards and paves the way for entry into Brazil, the largest pharmaceutical market in South America."

The successful ANVISA audit marks a significant achievement for Haleos Labs Limited, potentially opening doors to new business opportunities and reinforcing its position in the global pharmaceutical API manufacturing industry. As the company continues its rebranding process and expands its international footprint, investors and industry observers will likely keep a close watch on its progress in the Brazilian market and beyond.

SMS Lifesciences India Limited has announced key dates and initiatives for its shareholders, including a record date for dividend eligibility and a new campaign to address unclaimed dividends.

Record Date and Annual General Meeting

The company has fixed September 24, 2025, as the record date for two important purposes:

1. Determining shareholder eligibility for dividend payments for the financial year 2024-25
2. Establishing voting rights for the 19th Annual General Meeting (AGM)

The AGM is scheduled for September 30, 2025, at 3:00 pm. Shareholders on record as of September 24, 2025, will be entitled to participate in the voting process during the AGM.

Dividend Payment Details

If approved by shareholders at the AGM, the dividend will be paid within 30 days, subject to tax deduction at source. The company plans to credit the dividend directly to shareholders' bank accounts.

'Saksham Niveshak' Campaign Launch

SMS Lifesciences has launched the 'Saksham Niveshak' campaign to address unclaimed dividends and improve shareholder engagement. This 100-day initiative will run from July 28 to November 6, 2025, with the following objectives:

1. Reduce the quantum of unclaimed dividends
2. Facilitate KYC (Know Your Customer) updates for shareholders
3. Encourage bank mandate registrations
4. Assist shareholders in claiming unpaid dividends from 2018-19 to 2023-24

The campaign aims to prevent the transfer of shares and dividends to the Investor Education and Protection Fund Authority (IEPFA) by encouraging shareholders to update their records and claim entitlements directly from the company.

Shareholder Action Required

Eligible shareholders who have not yet claimed their dividends or updated their KYC details are urged to take action. They can contact the company's Registrar and Transfer Agent (RTA):

Aarthi Consultants Private Limited 1-2-285, Domalguda Hyderabad – 500029 Phone: 040 2763811 Email: info@aarthiconsultants.com

Compliance and Transparency

This initiative aligns with the Ministry of Corporate Affairs' circular dated July 16, 2025, and the Investor Education and Protection Fund Authority's efforts to empower investors. It demonstrates SMS Lifesciences' commitment to transparency, investor facilitation, and compliance with the Companies Act, 2013, and SEBI guidelines.

By taking these steps, SMS Lifesciences aims to enhance shareholder engagement and ensure that rightful claimants can easily update their records and claim their entitlements, thereby reducing the risk of share and dividend transfers to the IEPF.